Relative leucopenia and hemolytic anemia following infusion of immunoglobulin

Markvardsen, Lars Kjøbsted; Jakobsen, Johannes

doi:10.1111/ene.13444

Cited by 3 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IVIg infusions cause a rapid increase in serum immunoglobulin G with a sharp drop over the following 48 h, whereas SCIg maintains a relatively constant immunoglobulin G level. The absence of a rapid spike in serum immunoglobulin G levels post-infusion could explain the minor effect on circulating leucocytes, as already reported regarding hemolysis [3].…”

Section: E U R O P E a N J O U R N A L O F N E U R O L O G Y L E T T supporting

confidence: 62%

“…A previous study [3] showed that WBC count decreased after IVIg therapy, probably related to anti-neutrophil antibody transfusion. A larger decrease of WBC count correlated with a more effective treatment, raising speculation that a decrease in WBC count could represent an efficacy indicator of IVIg treatment.…”

mentioning

confidence: 90%

“…Although hemolysis is a well-known phenomenon, no clear evidence has been reported about the pathological mechanism of leucopenia during immunoglobulin therapy [2,3].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Subcutaneous immunoglobulin treatment and leucopenia in acquired demyelinating peripheral neuropathies

Vacchiano¹,

Liguori²,

Avoni³

et al. 2019

Euro J of Neurology

View full text Add to dashboard Cite

Section: E U R O P E a N J O U R N A L O F N E U R O L O G Y L E T T supporting

confidence: 62%

mentioning

confidence: 90%

See 1 more Smart Citation

Subcutaneous immunoglobulin treatment and leucopenia in acquired demyelinating peripheral neuropathies

Vacchiano¹,

Liguori²,

Avoni³

et al. 2019

Euro J of Neurology

View full text Add to dashboard Cite

“…Immunoglobulin therapy can cause hemolysis, but it can also cause neutropenia ( 97 ). In 1998, Majer et al ( 98 ) first described neutropenia as a complication of IVIG therapy in children with ITP.…”

Section: Classification Of Adverse Effectsmentioning

confidence: 99%

Adverse Effects of Immunoglobulin Therapy

et al. 2018

View full text Add to dashboard Cite

Immunoglobulin has been widely used in a variety of diseases, including primary and secondary immunodeficiency diseases, neuromuscular diseases, and Kawasaki disease. Although a large number of clinical trials have demonstrated that immunoglobulin is effective and well tolerated, various adverse effects have been reported. The majority of these events, such as flushing, headache, malaise, fever, chills, fatigue and lethargy, are transient and mild. However, some rare side effects, including renal impairment, thrombosis, arrhythmia, aseptic meningitis, hemolytic anemia, and transfusion-related acute lung injury (TRALI), are serious. These adverse effects are associated with specific immunoglobulin preparations and individual differences. Performing an early assessment of risk factors, infusing at a slow rate, premedicating, and switching from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG) can minimize these adverse effects. Adverse effects are rarely disabling or fatal, treatment mainly involves supportive measures, and the majority of affected patients have a good prognosis.

show abstract